68Ga-aGPC3-scFv/Fab

N/A

Report date: 2025/09/19 17:44:58

Base Information

Drug Name68Ga-aGPC3-scFv/Fab

Drug Alias Namegallium-68(68Ga)-aGPC3-scFv/Fab68Ga-aGPC3-scFv/Fab

ClassificationRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Gallium > 68Ga +[4]

Mechanisms of ActionAnti-Glypican-3Positron-emission tomography enhancers

TargetsGlypican-3

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesWuhan Union Hospital

China Registration ClassN/A

Develop Information

Active CompaniesWuhan Union Hospital

Inactive CompaniesN/A

Active IndicationsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A